Authors: Clarke-Pearson, DL Van Le, L Iveson, T Whitney, CW Hanjani, P Kristensen, G Malfetano, JH Beckman, RA Ross, GA Lane, SR DeWitte, MH Fields, SZ

Citation: Dl. Clarke-pearson et al., Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer, J CL ONCOL, 19(19), 2001, pp. 3967-3975

Authors: Gore, M Rustin, G Schuller, J Lane, SR Hearns, S Beckman, RA Ross, G

Citation: M. Gore et al., Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer, BR J CANC, 84(8), 2001, pp. 1043-1046

Authors: Cesano, A Lane, SR Ross, GA Fields, SZ

Citation: A. Cesano et al., Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients, INT J ONCOL, 17(3), 2000, pp. 587-590

Authors: Cesano, A Lane, SR Poulin, R Ross, G Fields, SZ

Citation: A. Cesano et al., Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients, INT J ONCOL, 15(6), 1999, pp. 1233-1238

Authors: von Pawel, J Schiller, JH Shepherd, FA Fields, SZ Kleisbauer, JP Chrysson, NG Stewart, DJ Clark, PI Palmer, MC Depierre, A Carmichael, J Krebs, JB Ross, G Lane, SR Gralla, R

Citation: J. Von Pawel et al., Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J CL ONCOL, 17(2), 1999, pp. 658-667